Ablynx: Balancing Partners And Pipeline
Next-generation antibody company Ablynx boasts a series of technology partnership deals but its primary goal is to develop drugs. Can partners’ money fund a pipeline with sufficient focus to be manageable, but enough breadth to survive?
You may also be interested in...
Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.
Post-Pfizer Deal Setback, Ablynx Finds Data Differentiating Its Nanobody Ozoralizumab From Other Anti-TNFs
Ablynx releases Phase II open-label extension clinical data showing its lead nanobody, ozoralizumab, allows individualized dosing in rheumatoid arthritis and doesn't induce neutralizing antibodies that affect efficacy, potentially differentiating it from marketed TNF inhibitors.
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.